<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201796</url>
  </required_header>
  <id_info>
    <org_study_id>027IC13250</org_study_id>
    <secondary_id>2014-003757-33</secondary_id>
    <nct_id>NCT03201796</nct_id>
  </id_info>
  <brief_title>Prulifloxacin in Chronic Bacterial Prostatitis (CBP)</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of Prulifloxacin vs Levofloxacin in the Treatment of Chronic Bacterial Prostatitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hippocrates Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy and safety of prulifloxacin in comparison to&#xD;
      levofloxacin in the treatment of patients affected by CBP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, levofloxacin controlled, parallel group, multicentre,&#xD;
      international, prospective study. The patients will be enrolled in the study and will be&#xD;
      randomized to prulifloxacin or levofloxacin. Patient enrolment will be competitive.&#xD;
&#xD;
      The present study is planned to verify the microbiological and the clinical efficacy of a&#xD;
      28-day treatment period with prulifloxacin 600 mg in comparison with 28-day treatment period&#xD;
      with levofloxacin 500 mg, both administered once daily, in patients with CBP. Safety and&#xD;
      tolerability of a 28-day treatment period with prulifloxacin 600 mg will be also evaluated in&#xD;
      comparison to levofloxacin 500 mg.&#xD;
&#xD;
      Levofloxacin 500 mg tablets has been selected as treatment comparator because it represents&#xD;
      the drug of choice authorised for the treatment of CBP. Consequently, the dosage regimen to&#xD;
      be administered to the patients is consistent with that reported in the relevant SPC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2016</start_date>
  <completion_date type="Actual">May 19, 2020</completion_date>
  <primary_completion_date type="Actual">May 19, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, levofloxacin controlled, multicentre, international, prospective study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The present study will be performed in double blind condition. Consequently, during the study, neither the Investigator nor the patient will be aware of the treatment assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication of bacterial growth</measure>
    <time_frame>7 days after the EOT</time_frame>
    <description>Eradication defined as absence of bacterial growth as &lt;10^2 CFU/ml in voided bladder 3 (VB3) or expressed prostatic secretion (EPS) after 7 days from the End Of Treatment (EOT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eradication of bacterial growth</measure>
    <time_frame>3 months after the EOT</time_frame>
    <description>Eradication defined as absence of bacterial growth as &lt;10^2 CFU/ml in voided bladder 3 (VB3) or expressed prostatic secretion (EPS) after 3 months from the EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication of bacterial growth</measure>
    <time_frame>6 months after the EOT</time_frame>
    <description>Eradication defined as absence of bacterial growth as &lt;10^2 CFU/ml in voided bladder 3 (VB3) or expressed prostatic secretion (EPS) after 6 months from the EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in National Institute of Health - Chronic Prostatitis Symptom (NIH-CPSI)</measure>
    <time_frame>Screening - 7 days after the EOT</time_frame>
    <description>Reduction of total score in NIH-CPSI after 7 days from the EOT in comparison to the screening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in National Institute of Health - Chronic Prostatitis Symptom (NIH-CPSI)</measure>
    <time_frame>Screening - 3 months after the EOT</time_frame>
    <description>Reduction of total score in NIH-CPSI after 3 months from the EOT in comparison to the screening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in National Institute of Health - Chronic Prostatitis Symptom (NIH-CPSI)</measure>
    <time_frame>Screening - 6 months after the EOT</time_frame>
    <description>Reduction of total score in NIH-CPSI after 6 months from the EOT in comparison to the screening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment-related adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Monitoring of the frequency of adverse events, physical examination, vital signs, ECG, laboratory analyses.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Chronic Bacterial Prostatitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prulifloxacin 600 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin 500 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prulifloxacin 600 mg</intervention_name>
    <description>Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Unidrox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 500mg</intervention_name>
    <description>Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Levoxacin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male between 18 and 50 years of age (limited included) with no limitation of race.&#xD;
&#xD;
          2. Patients presenting symptoms of prostatitis for at least 3 months.&#xD;
&#xD;
          3. Laboratory evidence of CBP at Visit 0 (Screening), assessed by&#xD;
&#xD;
             Meares&amp;Stamey fourglass test and defined as:&#xD;
&#xD;
               1. VB3 or EPS specimen containing ≥10^2 colony-forming units/ml of pathogen/s if the&#xD;
                  VB2 specimen is sterile; or&#xD;
&#xD;
               2. VB3 or EPS specimen containing ≥10^2 colony-forming units/ml of pathogen/s&#xD;
                  different from any present in the VB2.&#xD;
&#xD;
          4. Medications for chronic prostatitis and/or medications that may affect bladder or&#xD;
             prostate function (including but not limited to hormone therapy, anticholinergic or&#xD;
             alpha blocker) must be discontinued at least 7 days before study drug intake.&#xD;
&#xD;
          5. Patients legally capable to give their consent to participate the study, and available&#xD;
             to sign and date the written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity or allergy to antibacterial fluoroquinolones or to any&#xD;
             components of the study medications.&#xD;
&#xD;
          2. Pathogen/s resistant to the study drugs at Visit 0 (Screening).&#xD;
&#xD;
          3. Suspicion for prostatic cancer, neurogenic bladder, Benign Prostatic Hypertrophy&#xD;
             (BPH), bladder neck obstruction or urethral stricture.&#xD;
&#xD;
          4. Body Mass Index (BMI) &lt; 16 kg/m^2.&#xD;
&#xD;
          5. Immunocompromised patients.&#xD;
&#xD;
          6. Signs or symptoms or clinical documentation for concurrent infections (including but&#xD;
             not limited to sexually transmitted infections) and/or neoplasm.&#xD;
&#xD;
          7. Clinically significant abnormalities on physical examination, vital signs, ECG,&#xD;
             laboratory tests at Visit 0 (Screening Visit).&#xD;
&#xD;
          8. Significant liver disease, defined as known active hepatitis or elevated liver enzymes&#xD;
             &gt; 3 times the upper boundary of the normal ranges.&#xD;
&#xD;
          9. Value of creatinine outside the normal ranges and judged clinically relevant by&#xD;
             Investigator.&#xD;
&#xD;
         10. History of cardiac disease, including but not limited to myocardial infarction, heart&#xD;
             failure, cardiomyopathy, cardiac hypertrophy, cardiac arrhythmias, bradycardia,&#xD;
             cardiac conduction abnormalities, long QT syndrome.&#xD;
&#xD;
         11. Value of electrolytes (sodium, potassium, calcium, magnesium, chloride) outside the&#xD;
             normal ranges and judged clinically relevant by Investigator.&#xD;
&#xD;
         12. Patients under treatment with medications that may cause increase of the QT interval.&#xD;
&#xD;
         13. History of tendinopathy.&#xD;
&#xD;
         14. Patients with latent or known deficiencies for the glucose-6-phosphate dehydrogenase,&#xD;
             or with hereditary problems of galactose intolerance or the Lapp lactase deficiency or&#xD;
             glucose-galactose malabsorption.&#xD;
&#xD;
         15. Recent or past history of psychiatric illness or epilepsy.&#xD;
&#xD;
         16. Treatment with antibiotics or antibacterials within 2 weeks before study drug start&#xD;
             intake.&#xD;
&#xD;
         17. Treatment with experimental drugs (prulifloxacin or levofloxacin) or other&#xD;
             fluoroquinolones within 4 weeks before study drug start intake.&#xD;
&#xD;
         18. Diabetic patients in treatment with oral hypoglycemic drugs and insulin.&#xD;
&#xD;
         19. Patients under treatment with corticosteroids or Non-Steroidal Antiflammatory Drugs&#xD;
             (NSAIDs).&#xD;
&#xD;
         20. Concomitant treatment with xanthines or anticoagulant drugs or drugs producing&#xD;
             hypokalemia or diuretics.&#xD;
&#xD;
         21. Positive history for drugs and alcohol abuse.&#xD;
&#xD;
         22. Inability to comply with the protocol requirements, instructions or study-related&#xD;
             restrictions (i.e. uncooperative attitude, inability to return for study-visits,&#xD;
             improbability of completing the clinical study).&#xD;
&#xD;
         23. Vulnerable subjects (i.e. persons kept in detention).&#xD;
&#xD;
         24. Subject involved in the conduct of the study (i.e. Investigator or his/her deputy,&#xD;
             first grade relatives, pharmacist, assistant or other personnel).&#xD;
&#xD;
         25. Participation to an interventional clinical trial within 3 months prior to Visit 0&#xD;
             (Screening Visit).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Urology Clinic General Hospital of Athens &quot;GENNIMATAS&quot;</name>
      <address>
        <city>Athens</city>
        <zip>15669</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Department General Hospital of Piraeus &quot;TZANEIO&quot;</name>
      <address>
        <city>Piraeus</city>
        <zip>18536</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Urologia- Azienda Ospedaliera San Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Dipartimento della Donna, del bambino e delle malattie urologiche - Azienda ospedaliero- Universitaria e Policlinico di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologia- Azienda Ospedaliero - Universitaria &quot;Policlinico - Vittorio Emanuele&quot;</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Urologica- Azienda Ospedaliero Universitaria Mater Domini</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria &quot;Careggi&quot;</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria &quot;Federico II&quot;- Dip. Di Ostreticia, ginecologia, Urologia</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Urologica del Dipartimento di Scienze Chirurgiche- Policlinico Universitario Agostino Gemelli di Roma</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Urologia- AO &quot;Città della Salute e della Scienza&quot; di Torino - OSP.S. GIOV.BATTISTA MOLINETTE</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologia- Ospedale di Trento- Presidio ospedaliero S. Chiara - Azienda Provinciale per i servizi sanitari (APSS)</name>
      <address>
        <city>Trento</city>
        <zip>38123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.angelinipharma.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacterial prostatitis</keyword>
  <keyword>CBP</keyword>
  <keyword>Levofloxacin</keyword>
  <keyword>Prulifloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Prulifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

